Background: Vitamin D is critical for healthy pregnancies and normal fetal development. It is important to accurately
Introduction
Vitamin D insufficiency is associated with a number of adverse health outcomes and is increasingly recognized as a public health concern. Observational data suggest a link between low concentrations of vitamin D and an increased risk of adverse pregnancy outcomes, such as gestational diabetes, preeclampsia, infections, cesarean delivery, and fetal growth restriction (1) . Furthermore, because newborn vitamin D concentrations are largely dependent on maternal vitamin D status, infants of vitamin D-deficient mothers are at risk of deficiency (2) .
Although vitamin D has been implicated in the health of numerous organ systems, we lack critical knowledge on the optimal vitamin D biomarker status and intake during pregnancy that is required to reduce the risk of adverse health events (3, 4) . ecently, LC-tandem MS (LC-MS/MS) 9 methods have identified the epimeric form of 25-hydroxycholecalciferol [25(OH)D 3 ], which has been shown to contribute significantly to measured 25(OH)D 3 concentration, particularly in infants, but also in children and adults (5) . Little is known about the presence of these epimers in pregnancy and cord blood (6, 7) . Analytical methods, such as the commonly used ELISAs, which do not separate the epimer or other vitamin D metabolites (e.g., 24,25-dihydroxyvitamin D), may result in very different estimations of vitamin D status (8) . Although the physiologic functions of these epimers are not well understood (5), 3-epi-25-hydroxycholecalciferol [3-epi-25(OH)D 3 ], in particular, may represent up to 25% of total measured vitamin D concentrations in some assays in newborns (6) . The most active form of the epimer is thought to have <30% of the bioactivity of vitamin D (5) . The percentage of detectable 3-epi-25(OH)D 3 in sera has been reported to vary from 0% to 100% in adults and from 30% to 100% in infants (5) . Quantification methods that cannot distinguish between 25(OH)D 3 and 3-epi-25(OH)D 3 could lead to misclassification of vitamin D insufficiency because both substances would be measured as 25(OH)D 3 , which may underestimate those at risk of adverse health outcomes related to vitamin D insufficiency and prevent some individuals from receiving potentially important supplementation (5) .
The primary aim of this study was to measure 25-hydroxyvitamin D [25(OH)D] metabolites and epimers and their relation in maternal and cord blood in a cohort of healthy pregnant women at the time of delivery. Quantifying the concentrations of these forms of vitamin D in maternal-infant pairs permits the evaluation of the impact of including 3-epi-25(OH)D 3 in plasma total 25(OH)D when assessing vitamin D status. Furthermore, it facilitates the determination of the effects of maternal characteristics and vitamin D supplementation during pregnancy on these metabolites.
Methods
Pregnant women and their infants were recruited from the APrON (Alberta Pregnancy Outcomes and Nutrition) study (www.apronstudy.ca), a longitudinal cohort of pregnant women residing in Calgary and Edmonton (Alberta, Canada). APrON recruited women (n = 2191) between March 2009 and July 2012. Full details of the APrON study are described elsewhere (9) . The APrON-D study (substudy of APrON that looked at vitamin D in this cohort) recruited a subset of APrON participants during their third trimester and obtained consent to collect cord and maternal blood samples at the time of delivery. Women were eligible if they were delivering at participating maternity hospitals and had not previously committed to banking their cord blood. Data on skin type, sun exposure, sunscreen use, country of birth, and use of prenatal supplemental vitamin D were collected from all participants. These data were not available from the APrON database; however, previous studies have shown their confounding effect on vitamin D concentration (10) . Skin type was measured by using the Fitzpatrick scale (11), and skin color was measured by a trained research assistant with the use of the New Immigrant Survey scale (12) . All other data were obtained from the APrON database (9) . Cord blood sample collection materials, which included instructions for care providers, laboratory requisition, and blood collection tubes, were provided to participants, who were instructed to have the kit with them at the time of delivery. The laboratory requisition in the bag labeled ''Maternal Blood'' was labeled with the participantÕs name and APrON participant number. The laboratory requisition in the bag labeled ''Cord Blood'' was populated with the infantÕs APrON participant number and the motherÕs surname. All tubes in both bags were labeled with the participant number. To enhance compliance, each participant was sent a reminder e-mail near her due date, instructing her to put the APrON-D box into her delivery bag and to give it to the nurse or physician upon arrival at the hospital.
Blood assay. A maternal blood sample was collected within 30-60 min after delivery. Umbilical cord blood was collected immediately after delivery from the umbilical vein by the delivering physician and sent to the laboratory with routine cord blood samples. The blood samples were collected in evacuated tubes coated with potassium EDTA (K 2 EDTA) and centrifuged, and 6 mL plasma was stored at 270°C for 25(OH)D determination by using LC-MS/MS at DoctorÕs Data Laboratory (St. Charles, IL). With no established cutoff of 25(OH)D concentration for vitamin D insufficiency in pregnancy and cord blood, we used <50 nmol/L as recommended by Health Canada (3) and <75 nmol/L as recommended by Osteoporosis Canada (13) and the Endocrine Society (14) . 
Results
Ninety-two pairs of maternal and cord blood samples were available for analysis (sample characteristics are shown in Table 1 ).
All of the participants reported taking a daily vitamin D supplement and/or a prenatal multivitamin containing vitamin D during pregnancy. Information on supplement intake recording and analysis for the APrON study has been previously reported (15) . (5, 8) . Although the physiologic role of the C 3 -epimerization pathway has not yet been elucidated, there are indications that it has a biological role (16, 17) and, when confirmed, may become important in the future estimation of status. Studies at present have shown that the C 3 -epimers possess some but not all of the known calcemic and noncalcemic regulatory effects attributed to vitamin D (16, 17) . The C 3 epimer has been reported to have antiproliferative activity and differentiation activity only at amounts of ;30% and 10%, respectively, compared with nonepimeric vitamin D metabolites (16, 17) . This has led to the suggestion that the C 3 -epimers should not be included in calculating 25(OH)D concentrations in serum. Clinical data have indicated the presence of 3-epi-25(OH)D 3 in infants, children, and adults; and some studies have shown that 9% of infants and 3% of adults would be misclassified as sufficient if the epimer had not been identified in the quantification (5). Our study showed that 5% of pregnant mothers and 7% of their newborns were misclassified as having sufficient concentrations (>75 nmol/L) when 3-epi-25(OH)D 3 was included in their vitamin D status estimation. It is interesting that when we examined the cutoff of <50 mmol/L, the percentage was 2% for mothers but still 7% for newborns. The reason for the discrepancy for maternal blood was due to the very small number of women who had 25(OH)D 3 concentrations <50 nmol/L in our study. These findings emphasize the need for further identification of 3-epi-25(OH)D 3 in the assessment of vitamin D status in pregnant women and infants.
There is a lack of knowledge on the source of 3-epi-25(OH)D 3 in the literature. There have been reports on the effect of factors such as age, season, and vitamin D supplementation on 3-epi-25(OH)D 3 (5, 18) . In our study, we found that the amount of vitamin D reported as taken as a supplement was positively correlated with concentrations of 3-epi-25(OH)D 3 . This suggests that supplemental vitamin D could be a source/substrate for 3-epi-25(OH)D 3 . This is consistent with Bailey et al. (7) who reported a significant independent effect of oral vitamin D supplementation on maternal 3-epi-25(OH)D 3 . They also analyzed a sample of vitamin D supplements used by women in their study and showed that 13% of the total cholecalciferol was 3-epi-25(OH)D 3 , indicating that the ingested vitamin D supplements may have contributed directly to 3-epi-25(OH)D 3 . Additional research is required to identify the sources of 3-epi-25(OH)D 3 in pregnancy and this epimerÕs significance as a biomarker in assessing vitamin D status. We also showed that season correlates significantly with maternal 3-epi-25(OH)D 3 , suggesting an endogenous contribution related to sun exposure; however, this association was not seen for cord blood. It is difficult to speculate about the endogenous source of 3-epi-25(OH)D 3 in our study population, because all participants in our study were taking a supplement containing vitamin D. This factor needs to be explored in future studies. One of our studyÕs limitations is that the cohort was skewed toward more educated women with an annual income >70,000 Canadian dollars, which could influence the generalizability of study findings. A second limitation is the small sample size, which reduced the statistical power of the study, but our results support the need for a larger population study.
In conclusion, we showed the importance of how vitamin D status is measured in pregnant women and cord blood can influence the estimates of status. Using LC-MS/MS, we found a high degree of vitamin D insufficiency (plasma concentrations lower than the current reference range) and that classification of sufficiency was affected by inclusion of the C 3 -epimer in the estimation. Vitamin D deficiency/insufficiency has been associated with an increased risk of pregnancy and birth complications (1); therefore, it is important to accurately ascertain vitamin D status in mothers and their newborns in future studies to establish the optimal vitamin D concentration during pregnancy. Research is needed to understand the functional role and source of 3-epi-25(OH)D 3 in pregnancy and cord blood and its significance in the assessment of vitamin D status.
